Beta-Alanine: What Studies on Carnosine, Performance and Tingling Actually Show

Where beta-alanine works, and where it doesn't

Beta-alanine works, but only in a narrow window: between 60 and 240 seconds of high-intensity effort. Below that the effect is small, above that it disappears. Once you have that in mind, you immediately know whether the supplement fits your training.

Saunders 2017 in the British Journal of Sports Medicine pooled 40 studies with 1,461 participants and found a +2.85 % effect on efforts lasting 0.5 to 10 minutes, peaking between 1 and 4 minutes. For pure 1RM lifts and for endurance over 10 minutes, no reliable effect.

That fits the mechanism. Beta-alanine supplies the rate-limiting precursor for carnosine, which acts as a muscle acid buffer and neutralises the H+ (hydrogen ions) produced by glycolysis.

What happens in the muscle

Carnosine is a dipeptide of beta-alanine and histidine. It sits at high concentrations in skeletal muscle and stabilises pH during intense effort. Histidine is usually available in adequate amounts, beta-alanine isn't. That's why supplementing the latter works and supplementing histidine barely does.

A Bayesian dose-response analysis by Stegen et al. 2020 quantified it. Four weeks at 4 to 6 g per day raise muscle carnosine by an average 60 to 80 %, with peaks up to 100 %. Loading phases of 10 to 12 weeks can push it further, but the plateau is rarely reached.

Dose, protocol and the tingling

The ISSN position stand by Trexler et al. 2015 recommends 4 to 6 g per day for at least 4 weeks, split into 4 doses of 0.8 to 1.6 g. The split isn't cosmetic. It bypasses the only relevant side effect, paresthesia: the skin, scalp and ear tingling that hits a few minutes after intake.

In practice: a 1.6 g dose produces clear tingling that fades after 30 to 60 minutes. A 0.8 g dose usually stays below the threshold. Both are harmless. The compound itself is considered safe in healthy adults for up to six months of daily use.

An alternative is sustained-release formulations. A 2023 double-blind RCT shows that a slow-release tablet almost eliminates paresthesia without reducing carnosine uptake. The trial is small (n=24) and the products cost more, but the trade is worth it if the tingling bothers you.

Who benefits most

The solid data is on trained men aged 20 to 40, the typical study population. A 2024 systematic review in IJSNEM covering 18 studies and 331 trained young men confirms it: 14 of 18 trials show a positive effect on maximal exercise, 4 show nothing or a small negative.

Data on women is thinner, but the few trials that exist show comparable effects. In older adults beta-alanine is being studied as a sarcopenia adjunct. A December 2024 systematic review at 2.4 to 3.2 g per day finds early signs of improved endurance capacity, but no firm gains on strength or physical function yet.

The profile fits

• Middle-distance athletes (800 m, 1,500 m, 2k row)
• Combat sports with repeated high-intensity rounds (boxing, MMA, BJJ)
• CrossFit athletes on WODs lasting 1 to 5 minutes
• Strength training with high reps (sets of 20, drop sets, squat complexes)

If you mostly train 1RM lifts, pure sprints or marathons, you'll see little to nothing. Creatine is the better pick for the first case, and there's no reliable ergogenic lever for the last.

How it compares to creatine and caffeine

If you already use creatine (see the creatine article) and caffeine, beta-alanine fills the middle-intensity slot. The three act on different energy systems: creatine on the phosphate system (up to 10 seconds), beta-alanine on anaerobic glycolysis (60 to 240 seconds), and caffeine systemically through the central nervous system.

Co-supplementation with creatine has been studied in several trials and shows additive effects without interaction. Anyone in middle-distance work or combat sports can stack them. For pure strength work with low reps, creatine alone is enough.

What we don't know well yet

Three open questions:

• Muscle carnosine saturation is high but not maximal. Higher doses for longer might push the plateau further. Stegen and colleagues model that, hard RCTs are missing.
• The effect on resistance training is reported inconsistently. A 2025 systematic review on dosing for strength and power finds some signal in volume-heavy protocols, but the effect is smaller than for middle-distance work.
• Long-term safety beyond 6 months hasn't been systematically tested. The ISSN calls it unproblematic. That's a judgment, not proof.

Short version: the compound has a precise application window. Hit it and you get a small but reproducible advantage. Miss it and you save yourself the four weeks of dosing and the tingling.